Kelly Paul Edward, Chief Operating Officer of Relmada Therapeutics ($RLMD), made two open market purchases of company shares worth $284,000 over the past year. His most recent buy occurred on November 5, 2025. These purchases rank 1,203rd among nearly 5,000 insiders, below the average of $1.46 million per buyer and 3.3 transactions. He reported no open market sales in the last 365 days.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec. 12, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | COO | A | Stock Appreciation Rights | 828000 | $0.00 | 828,000.0000 | 33,191,622 | 9999.99% | 2.49% |
| Nov. 5, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Chief Operating Officer | P | Common Stock | 90000 | $2.20 | 502,295.0000 | 33,191,622 | 21.83% | 0.27% |
| June 26, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Chief Operating Officer | A | Stock Option (right to buy) | 400000 | $0.00 | 400,000.0000 | 30,408,890 | 9999.99% | 1.32% |
| May 16, 2025 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Chief Operating Officer | P | Common Stock | 200000 | $0.43 | 412,295.0000 | 30,408,890 | 94.21% | 0.66% |
| Sept. 9, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Director | P | Common Stock | 25000 | $2.59 | 212,295.0000 | 30,174,202 | 13.35% | 0.08% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Director | A | Stock Option (right to buy) | 43700 | $0.00 | 109,372.0000 | 30,132,170 | 66.54% | 0.15% |
| May 24, 2024 | RELMADA THERAPEUTICS, INC. | $RLMD | Kelly Paul Edward | Director | J | Stock Option (right to buy) | 43700 | $0.00 | 65,672.0000 | 30,132,170 | 39.96% | 0.15% |